Our results will provide oncologists with clinical information on the efficacy and safety of Niv+Ipi, and also suggest the potential of Niv+Ipi as a new first-line treatment option for PD-L1-positive advanced NSCLC. The gene discussed is CD274; the disease is non-small cell lung carcinoma.